Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors

Circulation: Heart Failure

Volumn 13, Issue 9, 2020, Pages E007197-

  Packer, Milton ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

autophagy; fasting; lysosomes; metformin; pharmacology

Indexed keywords

SIRTUIN 1;

ANIMAL; AUTOPHAGY; HEART FAILURE; HUMAN; METABOLISM; OXIDATIVE STRESS; PHARMACOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; HEART FAILURE; HUMANS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SIRTUIN 1; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85091126611     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.120.007197     Document Type: Article

References (95)

1. McMurray JJV, Solomon SD, Docherty KF, Jhund PS. The dapaglifozin and prevention of adverse outcomes in heart failure trial (DAPA-HF) in context. Eur Heart J. 2020;pii:ehz916. doi: 10.1093/eurheartj/ehz916
2. Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of beneft of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovasc Diabetol. 2019;18:129. doi: 10.1186/s12933-019-0938-6
3. Osataphan S, Macchi C, Singhal G, Chimene-Weiss J, Sales V, Kozuka C, Dreyfuss JM, Pan H, Tangcharoenpaisan Y, Morningstar J, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and-independent mechanisms. JCI Insight. 2019;4:e123130. doi: 10.1172/jci. insight.123130
4. Swe MT, Thongnak L, Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Lungkaphin A. Dapaglifozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. Clin Sci (Lond). 2019;133:2415-2430. doi: 10.1042/CS20190863
5. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydroge-nase. Nature. 2014;510:542-546. doi: 10.1038/nature13270
6. Kishore P, Boucai L, Zhang K, Li W, Koppaka S, Kehlenbrink S, Schiwek A, Esterson YB, Mehta D, Bursheh S, et al. Activation of K(ATP) channels suppresses glucose production in humans. J Clin Invest. 2011;121:4916-4920. doi: 10.1172/JCI58035
7. Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA. Comparison of the effects of pioglitazone and met-formin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes. 2008;57:24-31. doi: 10.2337/db07-0827
8. Yu P, Xu X, Zhang J, Xia X, Xu F, Weng J, Lai X, Shen Y. Liraglutide attenuates nonalcoholic fatty liver disease through adjusting lipid metabolism via SHP1/AMPK signaling pathway. Int J Endocrinol. 2019;2019:1567095. doi: 10.1155/2019/1567095
9. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434:113-118. doi: 10.1038/nature03354
10. Li Y, Wong K, Giles A, Jiang J, Lee JW, Adams AC, Kharitonenkov A, Yang Q, Gao B, Guarente L, et al. Hepatic SIRT1 attenuates hepatic ste-atosis and controls energy balance in mice by inducing fbroblast growth factor 21. Gastroenterology. 2014;146:539-49.e7. doi: 10.1053/j.gastro.2013.10.059
11. Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control of mito-chondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res. 2008;79:208-217. doi: 10.1093/cvr/cvn098
12. Itoh N, Ohta H. Pathophysiological roles of FGF signaling in the heart. Front Physiol. 2013;4:247. doi: 10.3389/fphys.2013.00247
13. Xiong S, Salazar G, Patrushev N, Ma M, Forouzandeh F, Hilenski L, Alexander RW. Peroxisome proliferator-activated receptor? coactivator-1a is a central negative regulator of vascular senescence. Arterioscler Thromb Vasc Biol. 2013;33:988-998. doi: 10.1161/ATVBAHA.112.301019
14. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF, Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res. 2007;100:1512-1521. doi: 10.1161/01.RES.0000267723.65696.4a
15. Planavila A, Redondo-Angulo I, Ribas F, Garrabou G, Casademont J, Giralt M, Villarroya F. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res. 2015;106:19-31. doi: 10.1093/cvr/cvu263
16. Alvarez-Guardia D, Palomer X, Coll T, Davidson MM, Chan TO, Feldman AM, Laguna JC, Vázquez-Carrera M. The p65 subunit of NF-kappaB binds to PGC-1alpha, linking infammation and metabolic disturbances in cardiac cells. Cardiovasc Res. 2010;87:449-458. doi: 10.1093/cvr/cvq080
17. Zhang Y, Liu Z, Zhou M, Liu C. Therapeutic effects of fbroblast growth factor-21 against atherosclerosis via the NF-kB pathway. Mol Med Rep. 2018;17:1453-1460. doi: 10.3892/mmr.2017.8100
18. Salazar G, Cullen A, Huang J, Zhao Y, Serino A, Hilenski L, Patrushev N, Forouzandeh F, Hwang HS. SQSTM1/p62 and PPARGC1A/PGC-1alpha at the interface of autophagy and vascular senescence. Autophagy. 2019; 16:1092-1110. doi: 10.1080/15548627.2019.1659612
19. Ren Z, Xiao W, Zeng Y, Liu MH, Li GH, Tang ZH, Qu SL, Hao YM, Yuan HQ, Jiang ZS. Fibroblast growth factor-21 alleviates hypoxia/reoxygenation injury in H9c2 cardiomyocytes by promoting autophagic fux. Int J Mol Med 2019;43:1321-1330. doi: 10.3892/ijmm.2019.4071
20. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18:1692-1700. doi: 10.1096/fj.04-2263com
21. Nozynski J, Zakliczynski M, Konecka-Mrowka D, Zielinska T, Zakliczynska H, Nikiel B, Mlynarczyk-Liszka J, Mrowka A, Zembala-Nozynska E, et al. Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann Transplant 2012;17:53-61. doi: 10.12659/aot.883223
22. Chokshi A, Drosatos K, Cheema FH, Ji R, Khawaja T, Yu S, Kato T Khan R, Takayama H, Knöll R, et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 2012;125:2844-2853. doi: 10.1161/CIRCULATIONAHA.111.060889
23. Wan X, Wen JJ, Koo SJ, Liang LY, Garg NJ. SIRT1-PGC1a-NFKB pathway of oxidative and infammatory stress during trypanosoma cruzi infection: benefts of SIRT1-targeted therapy in improving heart function in chagas disease PLoS Pathog. 2016;12:e1005954. doi: 10.1371/journal.ppat.1005954
24. Yuan Q, Zhou QY, Liu D, Yu L, Zhan L, Li XJ, Peng HY, Zhang XL, Yuan XC Advanced glycation end-products impair Na+/K+-ATPase activity in diabetic cardiomyopathy: role of the adenosine monophosphate-activated protein kinase/sirtuin 1 pathway. Clin Exp Pharmacol Physiol 2014;41:127-133. doi: 10.1111/1440-1681.12194
25. Hsu YJ, Hsu SC, Hsu CP, Chen YH, Chang YL, Sadoshima J, Huang SM, Tsai CS, Lin CY Sirtuin 1 protects the aging heart from contractile dysfunction mediated through the inhibition of endoplasmic reticulum stress-mediated apoptosis in cardiac-specifc sirtuin 1 knockout mouse model. Int J Cardiol 2017;228:543-552. doi: 10.1016/j.ijcard.2016.11.247
26. Mu W, Zhang Q, Tang X, Fu W, Zheng W, Lu Y, Li H, Wei Y, Li L, She Z, et al. Overexpression of a dominant-negative mutant of SIRT1 in mouse heart causes cardiomyocyte apoptosis and early-onset heart failure. Sci China Life Sci. 2014;57:915-924. doi: 10.1007/s11427-014-4687-1
27. Wang B, Yang Q, Sun YY, Xing YF, Wang YB, Lu XT, Bai WW, Liu XQ, Zhao YX Resveratrol-enhanced autophagic fux ameliorates myocardial oxidative stress injury in diabetic mice. J Cell Mol Med. 2014;18:1599-1611. doi: 10.1111/jcmm.12312
28. Planavila A, Iglesias R, Giralt M, Villarroya F. Sirt1 acts in association with PPARa to protect the heart from hypertrophy, metabolic dysregulation, and infammation. Cardiovasc Res. 2011;90:276-284. doi: 10.1093/cvr/cvq376
29. Kuno A, Hori YS, Hosoda R, Tanno M, Miura T, Shimamoto K, Horio Y Res-veratrol improves cardiomyopathy in dystrophin-defcient mice through SIRT1 protein-mediated modulation of p300 protein. J Biol Chem. 2013;288:5963-5972. doi: 10.1074/jbc.M112.392050
30. Russell LK, Mansfeld CM, Lehman JJ, Kovacs A, Courtois M, Safftz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP. Cardiac-specifc induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004;94:525-533. doi: 10.1161/01.RES. 0000117088.36577.EB
31. Fang WJ, Wang CJ, He Y, Zhou YL, Peng XD, Liu SK. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1a deacetylation. Acta Pharmacol Sin. 2018;39:59-73. doi: 10.1038/aps.2017.50
32. Kulikova TG, Stepanova OV, Voronova AD, Valikhov MP, Sirotkin VN, Zhirov IV, Tereshchenko SN, Masenko VP, Samko AN, Sukhikh GT. Pathological remodeling of the myocardium in chronic heart failure: role of PGC-1a. Bull Exp Biol Med. 2018;164:794-797. doi: 10.1007/s10517-018-4082-1
33. Oka SI, Sabry AD, Cawley KM, Warren JS. Multiple levels of PGC-1a dysregulation in heart failure. Front Cardiovasc Med. 2020;7:2. doi: 10.3389/fcvm.2020.00002
34. Akkafa F, Halil Altiparmak I, Erkus ME, Aksoy N, Kaya C, Ozer A, Sezen H, Oztuzcu S, Koyuncu I, Umurhan B. Reduced SIRT1 expression correlates with enhanced oxidative stress in compensated and decompensated heart failure. Redox Biol. 2015;6:169-173. doi: 10.1016/j.redox.2015.07.011
35. Lu TM, Tsai JY, Chen YC, Huang CY, Hsu HL, Weng CF, Shih CC, Hsu CP. Downregulation of Sirt1 as aging change in advanced heart failure. J Biomed Sci. 2014;21:57. doi: 10.1186/1423-0127-21-57
36. Sihag S, Cresci S, Li AY, Sucharov CC, Lehman JJ. PGC-1alpha and ERRal-pha target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol. 2009;46:201-212. doi: 10.1016/j.yjmcc.2008.10.025
37. Dou Q, Peng Y, Zhou B, Zhang K, Lin J, Dai X, Zhang L, Rao L. Association of Nicotinamide Phosphoribosyltransferase (NAMPT) gene polymorphisms and of serum NAMPT levels with dilated cardiomyopathy in a Chinese population. Int J Mol Sci. 2015;16:22299-22318. doi: 10.3390/ijms160922299
38. Wang S, Fu C, Wang H, Shi Y, Xu X, Chen J, Song X, Sun K, Wang J, Fan X, et al. Polymorphisms of the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene are associated with hypertrophic car-diomyopathy and not with hypertension hypertrophy. Clin Chem Lab Med. 2007;45:962-967. doi: 10.1515/CCLM.2007.189
39. Caragnano A, Aleksova A, Bulfoni M, Cervellin C, Rolle IG, Veneziano C, Barchiesi A, Mimmi MC8, Vascotto C, Finato N, et al. Autophagy and infam-masome activation in dilated cardiomyopathy. J Clin Med. 2019;8:E1519. doi: 10.3390/jcm8101519
40. Saito T, Asai K, Sato S, Hayashi M, Adachi A, Sasaki Y, Takano H, Mizuno K, Shimizu W. Autophagic vacuoles in cardiomyocytes of dilated cardiomyopa-thy with initially decompensated heart failure predict improved prognosis. Autophagy. 2016;12:579-587. doi: 10.1080/15548627.2016.1145326
41. Nandi SS, Duryee MJ, Shahshahan HR, Thiele GM, Anderson DR, Mishra PK. Induction of autophagy markers is associated with attenuation of miR-133a in diabetic heart failure patients undergoing mechanical unloading. Am J Transl Res. 2015;7:683-696.
42. Singh SR, Zech ATL, Geertz B, Reischmann-Düsener S, Osinska H, Prondzynski M, Krämer E, Meng Q, Redwood C, van der Velden J, et al. Activation of autophagy ameliorates cardiomyopathy in mybpc3-targeted knockin mice. Circ Heart Fail. 2017;10:e004140. doi: 10.1161/CIRCHEARTFAILURE. 117.004140.
43. Bhuiyan MS, Pattison JS, Osinska H, James J, Gulick J, McLendon PM, Hill JA, Sadoshima J, Robbins J. Enhanced autophagy ameliorates cardiac proteinopathy. J Clin Invest. 2013;123:5284-5297. doi: 10.1172/JCI70877
44. Yang J, He J, Ismail M, Tweeten S, Zeng F, Gao L, Ballinger S, Young M, Prabhu SD, Rowe GC, et al. HDAC inhibition induces autophagy and mito-chondrial biogenesis to maintain mitochondrial homeostasis during cardiac ischemia/reperfusion injury. J Mol Cell Cardiol. 2019;130:36-48. doi: 10.1016/j.yjmcc.2019.03.008
45. Morrice N, Mcilroy GD, Tammireddy SR, Reekie J, Shearer KD, Doherty MK, Delibegovic M, Whitfeld PD, Mody N. Elevated Fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice. Sci Rep. 2017;7:43782. doi: 10.1038/srep43782
46. Wang R, Yi X, Li X, Jiang X. Fibroblast growth factor-21 is positively associated with atrial fbrosis in atrial fbrillation patients with rheumatic heart disease. Int J Clin Exp Pathol. 2015;8:14901-14908.
47. Rusli F, Deelen J, Andriyani E, Boekschoten MV, Lute C, van den Akker EB, Müller M, Beekman M, Steegenga WT. Fibroblast growth factor 21 refects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice. Sci Rep. 2016;6:30484. doi: 10.1038/srep30484
48. Refsgaard Holm M, Christensen H, Rasmussen J, Johansen ML, Schou M, Faber J, Kistorp C. Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic infammation. ESC Heart Fail. 2019;6:983-991. doi: 10.1002/ehf2.12502
49. Yang H, Feng A, Lin S, Yu L, Lin X, Yan X, Lu X, Zhang C. Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxida-tion and lipid-lowering effects in the heart. Cell Death Dis. 2018;9:227. doi: 10.1038/s41419-018-0307-5
50. Tanajak P, Sa-Nguanmoo P, Wang X, Liang G, Li X, Jiang C, Chattipakorn SC, Chattipakorn N. Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre-diabetic rats. Acta Physiol (Oxf). 2016;217:287-299. doi: 10.1111/apha.12698
51. Rupérez C, Lerin C, Ferrer-Curriu G, Cairo M, Mas-Stachurska A, Sitges M, Villarroya J, Giralt M, Villarroya F, Planavila A. Autophagic control of cardiac steatosis through FGF21 in obesity-associated cardiomyopathy. Int J Car-diol. 2018;260:163-170. doi: 10.1016/j.ijcard.2018.02.109
52. Zhang J, Cheng Y, Gu J, Wang S, Zhou S, Wang Y, Tan Y, Feng W, Fu Y, Mellen N, et al. Fenofbrate increases cardiac autophagy via FGF21/SIRT1 and prevents fbrosis and infammation in the hearts of Type 1 diabetic mice. Clin Sci (Lond). 2016;130:625-641. doi: 10.1042/CS20150623
53. Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T, Tokuyama H, Wakino S, Itoh H. High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep. 2018;8:6791. doi: 10.1038/s41598-018-25054-y
54. Konari N, Nagaishi K, Kikuchi S, Fujimiya M. Mitochondria transfer from mesenchymal stem cells structurally and functionally repairs renal proximal tubular epithelial cells in diabetic nephropathy in vivo. Sci Rep. 2019;9:5184. doi: 10.1038/s41598-019-40163-y
55. Maeda S, Matsui T, Takeuchi M, Yamagishi S. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev. 2013;29:406-412. doi: 10.1002/dmrr.2407
56. Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013;304:F156-F167. doi: 10.1152/ajprenal.00409.2012
57. Li S, Wang N, Guo X, Li J, Zhang T, Ren G, Li D. Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption. Biomed Pharmacother. 2018;108:355-366. doi: 10.1016/j.biopha.2018.09.078
58. Ying Y, Jiang C, Zhang M, Jin J, Ge S, Wang X. Phloretin protects against cardiac damage and remodeling via restoring SIRT1 and anti-infammatory effects in the streptozotocin-induced diabetic mouse model. Aging (Albany NY). 2019;11:2822-2835. doi: 10.18632/aging.101954
59. Mohamed HE, Asker ME, Keshawy MM, Hasan RA, Mahmoud YK. Inhibition of tumor necrosis factor-a enhanced the antifbrotic effect of empa-glifozin in an animal model with renal insulin resistance. Mol Cell Biochem. 2020;466:45-54. doi: 10.1007/s11010-020-03686-x
60. Wei D, Liao L, Wang H, Zhang W, Wang T, Xu Z. Canaglifozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARa in vivo and in vitro. Life Sci. 2020;247:117414. doi: 10.1016/j.lfs.2020.117414
61. Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, Mayoux E, Kaneko S, Ota T. SGLT2 inhibition by empaglifozin promotes fat utilization and browning and attenuates infammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137-149. doi: 10.1016/j.ebiom.2017.05.028
62. Aragón-Herrera A, Feijóo-Bandín S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, Costa Pereira TM, García-Caballero T, Rodríguez-Segade S, Rodríguez J, et al. Empaglifozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170:113677. doi: 10.1016/j.bcp. 2019.113677
63. Mizuno M, Kuno A, Yano T, Miki T, Oshima H, Sato T, Nakata K, Kimura Y, Tanno M, Miura T. Empaglifozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. Physiol Rep. 2018;6:e13741. doi: 10.14814/phy2.13741
64. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, et al. Inhibition of the glucose transporter SGLT2 with dapaglifozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512-517. doi: 10.1038/nm.3828
65. Ng KM, Lau YM, Dhandhania V, Cai ZJ, Lee YK, Lai WH, Tse HF, Siu CW. Empaglifozin ammeliorates high glucose induced-cardiac dysfun-tion in human iPSC-derived cardiomyocytes. Sci Rep. 2018;8:14872. doi: 10.1038/s41598-018-33293-2
66. Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapaglifozin reduces the activation of the Nlrp3/ASC infamma-some and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxa-gliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31:119-132. doi: 10.1007/s10557-017-6725-2
67. Mancini SJ, Boyd D, Katwan OJ, Strembitska A, Almabrouk TA, Kennedy S, Palmer TM, Salt IP. Canaglifozin inhibits interleukin-1ß-stimulated cyto-kine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and-independent mechanisms. Sci Rep. 2018;8:5276. doi: 10.1038/s41598-018-23420-4
68. Chen R, Xu M, Hogg RT, Li J, Little B, Gerard RD, Garcia JA. The acety-lase/deacetylase couple CREB-binding protein/sirtuin 1 controls hypoxia-inducible factor 2 signaling. J Biol Chem. 2012;287:30800-30811. doi: 10.1074/jbc.M111.244780
69. Schönenberger MJ, Krek W, Kovacs WJ. EPAS1/HIF-2a is a driver of mammalian pexophagy. Autophagy. 2015;11:967-969. doi: 10.1080/15548627.2015.1045180
70. Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest. 2005;35(suppl 3):13-19. doi: 10.1111/j.1365-2362.2005.01525.x
71. Cui S, Tanabe O, Lim KC, Xu HE, Zhou XE, Lin JD, Shi L, Schmidt L, Campbell A, Shimizu R, et al. PGC-1 coactivator activity is required for murine erythropoiesis. Mol Cell Biol. 2014;34:1956-1965. doi: 10.1128/MCB.00247-14
72. Cui L, Guo J, Zhang Q, Yin J, Li J, Zhou W, Zhang T, Yuan H, Zhao J, Zhang L, et al. Erythropoietin activates SIRT1 to protect human cardiomyo-cytes against doxorubicin-induced mitochondrial dysfunction and toxicity. Toxicol Lett. 2017;275:28-38. doi: 10.1016/j.toxlet.2017.04.018
73. Hong T, Ge Z, Zhang B, Meng R, Zhu D, Bi Y. Erythropoietin suppresses hepatic steatosis and obesity by inhibiting endoplasmic reticulum stress and upregulating fbroblast growth factor 21. Int J Mol Med. 2019;44:469-478. doi: 10.3892/ijmm.2019.4210
74. Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, Teoh H, Leiter LA, Zinman B, Jüni P, et al. Effect of empaglifozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2020;141:704-707. doi: 10.1161/CIRCULATIONAHA.119.044235
75. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, et al. How does empa-glifozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:356-363. doi: 10.2337/dc17-1096
76. Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW, de Zeeuw D, Vercruysse F, Shaw W, Matthews DR, et al. Mediators of the effects of canaglifozin on heart failure in patients with type 2 diabetes. JACC Heart Fail. 2020;8:57-66. doi: 10.1016/j.jchf.2019.08.004
77. McNally JS, Saxena A, Cai H, Dikalov S, Harrison DG. Regulation of xanthine oxidoreductase protein expression by hydrogen peroxide and calcium. Arterioscler Thromb Vasc Biol. 2005;25:1623-1628. doi: 10.1161/01.ATV.0000170827.16296.6e
78. Battelli MG, Polito L, Bortolotti M, Bolognesi A. Xanthine oxidoreductase-derived reactive species: physiological and pathological effects. Oxid Med Cell Longev. 2016;2016:3527579. doi: 10.1155/2016/3527579
79. Lappas M, Andrikopoulos S, Permezel M. Hypoxanthine-xanthine oxidase down-regulates GLUT1 transcription via SIRT1 resulting in decreased glucose uptake in human placenta. J Endocrinol. 2012;213:49-57. doi: 10.1530/JOE-11-0355
80. Huang XF, Li HQ, Shi L, Xue JY, Ruan BF, Zhu HL. Synthesis of resve-ratrol analogues, and evaluation of their cytotoxic and xanthine oxi-dase inhibitory activities. Chem Biodivers. 2008;5:636-642. doi: 10.1002/cbdv.200890059
81. Wang Z, Ding J, Luo X, Zhang S, Yang G, Zhu Q, Liu D. Effect of allopu-rinol on myocardial energy metabolism in chronic heart failure rats after myocardial infarct. Int Heart J. 2016;57:753-759. doi: 10.1536/ihj. 16-149
82. Furuhashi M, Matsumoto M, Murase T, Nakamura T, Higashiura Y, Koyama M, Tanaka M, Moniwa N, Ohnishi H, Saitoh S, et al. Independent links between plasma xanthine oxidoreductase activity and levels of adipokines. J Diabetes Investig. 2019;10:1059-1067. doi: 10.1111/jdi.12982
83. Cuevas-Ramos D, Almeda-Valdes P, Gómez-Pérez FJ, Meza-Arana CE, Cruz-Bautista I, Arellano-Campos O, Navarrete-López M, Aguilar-Salinas CA Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fbroblast growth factor 21 levels. Eur J Endocrinol. 2010;163:469-477. doi: 10.1530/EJE-10-0454
84. Wang J, Zhu XX, Liu L, Xue Y, Yang X, Zou HJ. SIRT1 prevents hyperuricemia via the PGC-1a/PPARy-ABCG2 pathway. Endocrine. 2016;53:443-452. doi: 10.1007/s12020-016-0896-7
85. Lu YH, Chang YP, Li T, Han F, Li CJ, Li XY, Xue M, Cheng Y, Meng ZY, Han Z, et al. Empaglifozin attenuates hyperuricemia by upregulation of ABCG2 via AMPK/AKT/CREB signaling pathway in type 2 diabetic mice. Int J Biol Sci 2020;16:529-542. doi: 10.7150/ijbs.33007
86. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care. 2016;39:1108-1114. doi: 10.2337/dc16-0330
87. Baker HE, Kiel AM, Luebbe ST, Simon BR, Earl CC, Regmi A, Roell WC Mather KJ, Tune JD, Goodwill AG. Inhibition of sodium-glucose cotrans-porter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Res Cardiol. 2019;114:25. doi: 10.1007/s00395-019-0733-2
88. Rojas-Morales P, Tapia E, Pedraza-Chaverri J. |3-Hydroxybutyrate: a signaling metabolite in starvation response? Cell Signal. 2016;28:917-923. doi: 10.1016/j.cellsig.2016.04.005
89. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D'Agostino D, Planavsky N, Lupfer C, Kanneganti TD, et al. The ketone metabolite |3-hydroxybutyrate blocks NLRP3 infammasome-mediated infammatory disease. Nat Med. 2015;21:263-269. doi: 10.1038/nm.3804
90. Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, Thorens B, Vaulont S, Viollet B. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes. 2005;54:1331-1339. doi: 10.2337/diabetes.54.5.1331
91. Yang Q, Guo X, Yang L. Metformin enhances the effect of regorafenib and inhibits recurrence and metastasis of hepatic carcinoma after liver resection via regulating expression of hypoxia inducible factors 2a (HIF-2a) and 30 kDa HIV Tat-interacting protein (TIP30). Med Sci Monit 2018;24:2225-2234. doi: 10.12659/msm.906687
92. 92.Diabetes Prevention Program Research Group. Long-term safety, tol-erability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care. 2012;35:731-737. doi: 10.2337/dc11-1299
93. Nistala R, Raja A, Pulakat L. mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats. Can J Physiol Pharmacol. 2017;95:281-287. doi: 10.1139/cjpp-2016-0567
94. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M, Kim J, Minamino T, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009;119:2568-2577. doi: 10.1161/CIRCULATIONAHA.108.798561
95. Packer M. Is metformin benefcial for heart failure in patients with type 2 diabetes? Diabetes Res Clin Pract 2018;136:168-170. doi: 10.1016/j.diabres.2017.12.011